TICKERNERD
Menu
BTAIBTAIHealthcare · Drug Manufacturers - Specialty & Generic

BTAI Stock Forecast: BioXcel Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 24 Aug 2026
$0.76
−5.40% on the day

The 3 Wall Street analysts covering BioXcel Therapeutics, Inc. hold a median 12-month price target of $12 — +1477.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 31 of 100 as at 22 Aug 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$25.2M
Ticker Nerd rank
31 / 100
Median analyst target
$12
Analysts covering
3
Revenue$206K+22.6% y/y
Operating income−$10.2M
Net income−$12.7M
Free cash flow−$11.8M
Quarterly, 8 quarters to 31 Mar 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−14.5%
1M
−10.3%
YTD
−52.5%
1Y
−84.7%
From 52W high
−85.5%
From 52W low
0.0%
$0.76
$5.24
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

BTAI stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores BioXcel Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
31 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
87
Accruals
83
Issuance
55
Growth
47
Revisions
47
Volatility
27
Value
21
Quality
15
Momentum
6

Size (87): Smaller than most of the companies we track.

Momentum (6): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

BTAI stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on BTAI, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$10.00$20.00$30.00$40.00Oct 25Jan 26Apr 26Jul 26BTAIHigh $38Median $12Low $5

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says3 analysts
3 Buy0 Hold0 Sell
Low $5Median $12High $38

The green dot is the last close — the median target sits +1477.7% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
2 Apr 2026HC Wainwright & Co.MaintainsBuy$6.00 → $5.00
17 Mar 2026Rodman & RenshawInitiatesBuy—
5 Mar 2026HC Wainwright & Co.MaintainsBuy—
15 Sept 2025HC Wainwright & Co.ReiteratesBuy—
12 Sept 2025MizuhoMaintainsNeutral—
28 Aug 2025HC Wainwright & Co.ReiteratesBuy—
19 Aug 2025HC Wainwright & Co.ReiteratesBuy—
15 Aug 2025HC Wainwright & Co.MaintainsBuy—
15 July 2025LUCID CAPITAL MARKETSReiteratesBuy—
23 June 2025HC Wainwright & Co.MaintainsBuy—
19 Mar 2025Rodman & RenshawInitiatesBuy—
30 Jan 2025HC Wainwright & Co.MaintainsBuy—
7 Jan 2025B of A SecuritiesDowngradeUnderperform—
6 Jan 2025Canaccord GenuityMaintainsBuy—
21 Oct 2024HC Wainwright & Co.MaintainsBuy—
6 Sept 2024HC Wainwright & Co.ReiteratesBuy—
30 Aug 2024Canaccord GenuityMaintainsBuy—
9 Aug 2024UBSMaintainsNeutral—
8 Aug 2024HC Wainwright & Co.MaintainsBuy—
27 June 2024Canaccord GenuityMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. BTAI appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

BTAI vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 24 Aug 2026, BioXcel Therapeutics, Inc. returned −84.7% against +19.6% for the S&P 500, dividends included.

BTAI vs S&P 500, last 12 monthsTotal return, rebased to 100
020406080100120Oct 25Jan 26Apr 26Jul 26BTAIS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

BTAI analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

BioXcel Therapeutics, Inc. (BTAI) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−0.1×

Cheaper than 77% of US stocks

Price / sales
33.9×

Cheaper than 7% of US stocks

Price / book
−0.2×

Cheaper than 93% of US stocks

EV / EBITDA
−2.6×

Cheaper than 73% of US stocks

Growth & margins
Revenue growth (YoY)
51.7%

Higher than 87% of US stocks

Earnings growth (YoY)
22.6%

Higher than 61% of US stocks

Gross margin
−37.4%

Higher than 3% of US stocks

Operating margin
−5600.5%

Higher than 3% of US stocks

Net margin
74.5%

Higher than 98% of US stocks

Returns & dividend
Return on equity
73.2%

Higher than 95% of US stocks

Return on assets
−102.4%

Higher than 2% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

BioXcel Therapeutics, Inc. (BTAI) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • BioXcel Therapeutics, Inc. has a market value of $25.2M and an enterprise value of $116.8M.

  • Revenue in the twelve months to 31 Mar 2026: $680K. The latest quarter grew 51.7% year on year.

  • Net income over the same four quarters: −$75.3M, a −11078.5% net margin.

  • Free cash flow in the twelve months to 31 Mar 2026: −$57.4M, after $0.0 of capital spending.

  • Shares outstanding: 27.1M.

  • Trailing P/E: −0.1×; forward P/E: −0.5× — the forward figure prices analyst consensus estimates, not reported earnings.

  • BioXcel Therapeutics, Inc. employs 29 people — $23K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 31 Mar 2026 · market figures as at 25 Aug 2026

Data provided by Twelve Data

Peers

BTAI vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - Specialty & Generic
CompanyMarket capTKN rank
BTAIBioXcel Therapeutics, Inc.$25.2M
31
AYTUAytu Biopharma, Inc.$25.4M
62
TXMDTherapeuticsMD, Inc.$23.8M
79
UPCUniverse Pharmaceuticals, Inc.$26.6M
30
OPTHOptimi Health Corp.$27.4M
15
BFRIBiofrontera, Inc.$22.0M
66
RMTIRockwell Medical, Inc.$32.0M
49

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own BioXcel Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest BTAI news & analysis

BioXcel Therapeutics, Inc. (BTAI) Reports Q2 Loss, Misses Revenue Estimates

Zacks Investment Research · 14 Aug 2026neutral

BioXcel Therapeutics reported a second-quarter loss of $0.49 per share, narrower than the Zacks Consensus Estimate of a $0.51 loss and improved from a $2.45 per share loss a year ago, while revenue missed estimates.

Why it matters — The quarterly loss was smaller than both analyst expectations and the prior-year figure, though the revenue miss is a metric shareholders track closely.

FAQ

Frequently asked questions about BTAI stock

What is the BTAI stock price forecast for 2026-2027?

The 3 Wall Street analysts covering BioXcel Therapeutics, Inc. have a median 12-month price target of $12, with estimates ranging from $5 to $38. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is BTAI stock a buy right now?

Of the 3 analysts covering BioXcel Therapeutics, Inc., 3 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks BioXcel Therapeutics, Inc. 31 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank BTAI?

As at 22 Aug 2026, BioXcel Therapeutics, Inc. ranks 31 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (87 of 100).

Will BTAI stock go up?

No one can know that. What the data says: the median 12-month target from 3 analysts implies +1477.7% from the last close, and Ticker Nerd's factor model ranks BioXcel Therapeutics, Inc. 31 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the BTAI stock forecast for 2030?

No analyst covering BioXcel Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BTAI are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $5 to $38 over the next 12 months.

How has BTAI stock performed over the past year?

BioXcel Therapeutics, Inc. returned -84.7% over the 12 months to 24 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does BioXcel Therapeutics, Inc. do?

BioXcel Therapeutics, Inc. is a biopharmaceutical company that leverages artificial intelligence to develop innovative medicines in neuroscience and immuno-oncology.

What is the latest news on BTAI?

The most recent item we track (Zacks Investment Research, 14 Aug 2026): "BioXcel Therapeutics, Inc. (BTAI) Reports Q2 Loss, Misses Revenue Estimates". BioXcel Therapeutics reported a second-quarter loss of $0.49 per share, narrower than the Zacks Consensus Estimate of a $0.51 loss and improved from a $2.45 per share loss a year ago, while revenue missed estimates.

Company

About BioXcel Therapeutics, Inc.

BioXcel Therapeutics, Inc. is a biopharmaceutical company that leverages artificial intelligence to develop innovative medicines in neuroscience and immuno-oncology. Its lead product, IGALMI, is a sublingual film approved for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The company advances BXCL501, an investigational orally dissolving film formulation of dexmedetomidine in Phase 3 trials targeting agitation in bipolar disorders, schizophrenia, Alzheimer’s disease, opioid use disorder, alcohol use disorder with comorbid post-traumatic stress disorder, and acute stress disorder. In immuno-oncology, BXCL701 is an oral innate immune activator that has completed Phase 1b/2a trials for aggressive prostate cancer, pancreatic cancer, and other solid and liquid tumors. Additional pipeline candidates include BXCL502 for stress-related neuropsychiatric symptoms in dementia, BXCL503 to target apathy in dementia, and BXCL504 addressing apathy and aggression in dementia. Through collaborations with institutions like Columbia University, Yale University Medical School, and University of North Carolina, BioXcel Therapeutics, Inc. focuses on AI-driven drug discovery to address unmet needs in behavioral health and cancer therapies. Incorporated in 2017 and headquartered in New Haven, Connecticut, it operates as a clinical-stage biopharma player in the United States.

CEO Dr. Vimal D. Mehta Ph.D. · 29 employees · United States · https://www.bioxceltherapeutics.com